摘要
目的分析骨质疏松症患者使用阿仑膦酸钠联合骨肽注射液治疗的临床效果和影响。方法将我院2013年5月-2015年8月收治的500例骨质疏松症患者作为分析对象,按照随机分组方式分成对照组和试验组各250例,对照组患者采取阿仑膦酸钠治疗骨质疏松症,而试验组患者在对照组基础之上联合骨肽注射液治疗骨质疏松症,对比两组患者的临床治疗总有效率、治疗前后股骨密度的改善情况和临床不良反应率。结果对照组患者的临床治疗总有效率(72.0%)明显低于试验组(96.80%),差异具有统计学意义(P<0.05);试验组患者在治疗后骨密度情况明显优于对照组;试验组患者的临床不良反应率(6.80%)明显优于对照组(40.0%),组间差异具有统计学意义(P<0.05)。结论骨质疏松症患者使用阿仑膦酸钠联合骨肽注射液治疗的临床效果良好,可以有效提高患者的骨密度。
Objective to investigate the clinical efficacy of alendronate combined with ossotide injection in treating osteoporosis.Methods five hundred patients hospitalized between May 2013 and August 2015 were included in our study. Patients were randomised into two groups,with 250 patients in the experimental group and the others in the control group. Alendronate combined with ossotide injection was used in the experimental group,and alendronate alone was used in the control group. The clinical efficacy was compared between two groups. Results The experimental group showed significantly better clinical efficacy compared with the control group（96. 80% vs 72. 0%,P〈0. 05）. The experimental group showed significantly greater bone mineral density（BMD） improvement compared with the control group,and had less adverse complication incidence（6. 80% vs40. 0%,P〈0. 05）. Conclusion Alendronate combined with the ossotide showed better clinical efficacy in the treatment of osteoporosis.
出处
《中国骨质疏松杂志》
CAS
CSCD
北大核心
2017年第6期784-786,共3页
Chinese Journal of Osteoporosis
基金
河南省医学重点学科临床特色专科学术技术带头人出国培训计划项目(2014095)
